( 1 ) Findings failed to support the existence of a dose-response relationship between maternal buprenorphine dose at delivery and any of 10 neonatal clinical outcomes , including NAS severity and ( 2 ) that infants treated for NAS had a higher mean NAS peak score and , spent a longer time in the hospital than did the group not treated for NAS is unsurprising .